The FDA has rejected vatiquinone, requesting that PTC run an additional study to prove the drug's efficacy prior to ...

Police said the incident occurred around 3:30 pm when Suryansh went to the teacher’s home carrying a petrol-filled bottle. He ...

Pioneer Theatre Company will present a developmental reading in advance of its upcoming world premiere of Ten Brave Seconds ...

Today, the FDA issued a complete response letter (CRL) for vatiquinone (PTC Therapeutics), delaying its potential approval as a treatment for Friedreich ataxia amid efficacy concerns.

PTC is demonstrating robust growth and consistent profitability, and analyst sentiment has grown more favorable recently.

Special Report: Pursuit Minerals’ PFS for a 5,000tpa lithium carbonate operation at Rio Grande Sur in Argentina is on track, with the final pond design for stage 1 complete. Several milestones have ...

This paper presents a new multilevel converter topology suitable for very high voltage applications, especially network interties in power generation and transmission. The fundamental concept and the ...

The original NDA submission included data from the registration-directed phase 3 MOVE-FA trial as well as 2 long-term studies evaluating vatiquinone in FA.

The small molecule, vatiquinone, had already flunked a Phase III trial, but the company pushed ahead with an approval bid ...

FDA rejected PTC Therapeutics' vatiquinone for Friedreich's ataxia, citing insufficient efficacy data and requiring another ...